ArticleCommunications biology2026
An rRNA-depleted full-length transcriptome strategy using nanopore sequencing for identification of novel lncRNA isoforms.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Long non-coding RNAs (lncRNAs) play crucial roles in gene regulation, but their full-length isoforms are often missed because of the limitations of poly(A)-based enrichment and short-read sequencing. Here, we aim to establish a comprehensive transcriptome profiling that captures both poly(A)+ and poly(A)- RNA isoforms using Oxford Nanopore Technologies (ONT) R10.4.1 flowcells. We establish an rRNA-depleted full-length transcriptome sequencing workflow (NanoncRNA-Seq), and use it together with Illumina NovaSeq to profile lncRNA isoforms in Saccharomyces cerevisiae under glucose and ethanol-associated physiological states. We combine multiple analytical tools to evaluate expression levels, splicing patterns, variants, and lncRNA identification. ONT sequencing achieves high accuracy (Q-score: 22.35, 99.42%) and detects fewer SNP and more novel isoforms, while Illumina sequencing reports fewer INDELs. Expression profiles are highly consistent within each platform and moderately across platforms. Notably, NanoncRNA-seq enables isoform-resolved lncRNA discovery and recoveres substantially more lncRNAs than Illumina (Pinfish: n = 260; Illumina: n = 51), including more lincRNAs (n = 201 vs. n = 25), likely because low-abundance transcripts are difficult to reconstruct from short reads. Overall, NanoncRNA-Seq effectively captures full-length lncRNA isoform discovery and highlights the complementary strengths of ONT in transcriptome research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.